CWM
XPH icon

Compass Wealth Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Compass Wealth Management’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
26,652
+2,499
+10% +$146K 0.33% 75
2026
Q1 		$1.31M Buy
24,153
+6,446
+36% +$359K 0.32% 67
2025
Q4 		$992K Buy
+17,707
New +$918K 0.25% 70

Other funds holding XPH

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
KWM
Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
EP
Evelyn Partners London $46.9B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Compass Wealth Management's XPH Position: Q2 2026 in Review

Compass Wealth Management increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 10% in Q2 2026, buying an estimated $146K and bringing the position to 26,652 shares worth $1.77M. The position accounts for 0.33% of the portfolio, ranked #75.

Compass Wealth Management first reported a position in XPH in Q4 2025 and has held it in 3 quarters since. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

  • Compass Wealth Management held 26,652 shares of State Street SPDR S&P Pharmaceuticals ETF worth $1.77M as of Q2 2026.
  • Compass Wealth Management bought 2,499 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $146K.
  • State Street SPDR S&P Pharmaceuticals ETF made up 0.33% of Compass Wealth Management's portfolio in Q2 2026, its #75 holding.
  • Compass Wealth Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2025 and has held it in 3 quarters since.
  • 93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Compass Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.